



Sophiris Bio Inc.
 Investor Relations Department
 1258 Prospect Street
 La Jolla, CA 92037
 United States

Visit IR website [↗](#)
 Sign-up for email alerts [↗](#)

NASDAQ: SPHS ¹

Last Trade:	2.07
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	0.00 (0.000%)
Day Range	2.02 - 2.12
52-Week Range	1.83 - 8.55
Volume	157,786
Market Cap. (\$M)	62.328
Shares Out (M)	30.110


¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris has initiated a Phase 2a proof of concept study of PRX302 for the treatment of localized low to intermediate risk prostate cancer during the 2nd quarter of 2015.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 23, 2017*
[Sophiris Bio Added to Russell Microcap Index](#)
- Jun 8, 2017*
[Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer](#)
- May 23, 2017*
[Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer](#)
- May 15, 2017*
[Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights](#)
- May 15, 2017*
[Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association \(AUA\) Meeting](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 27, 2017*
[Annual Report \(10-K\)](#)
- Apr 13, 2017*
[Definitive Proxy Statement](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*
[Quarterly Report \(10-Q\)](#)